Edwards Lifesciences Corporation (NYSE: EW) stock closed at 82.73 per share at the end of the most recent trading day (a 1.42% change compared to the prior day closing price) with a volume of 2.76M shares and market capitalization of 50.14B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14900 people. Edwards Lifesciences Corporation CEO is Michael A. Mussallem.

The one-year performance of Edwards Lifesciences Corporation stock is -30.71%, while year-to-date (YTD) performance is 10.88%. EW stock has a five-year performance of 77.89%. Its 52-week range is between 67.13 and 131.1, which gives EW stock a 52-week price range ratio of 24.39%

Edwards Lifesciences Corporation currently has a PE ratio of 33.20, a price-to-book (PB) ratio of 7.66, a price-to-sale (PS) ratio of 11.70, a price to cashflow ratio of 37.00, a PEG ratio of 2.32, a ROA of 15.77%, a ROC of 22.22% and a ROE of 22.59%. The company’s profit margin is 27.85%, its EBITDA margin is 36.80%, and its revenue ttm is $4.03 Billion , which makes it $6.52 revenue per share.

Of the last four earnings reports from Edwards Lifesciences Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.61 for the next earnings report. Edwards Lifesciences Corporation’s next earnings report date is 25th Apr 2023.

The consensus rating of Wall Street analysts for Edwards Lifesciences Corporation is Moderate Buy (1.97), with a target price of $96.53, which is +16.68% compared to the current price. The earnings rating for Edwards Lifesciences Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edwards Lifesciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edwards Lifesciences Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.30, ATR14 : 1.96, CCI20 : 102.94, Chaikin Money Flow : 0.08, MACD : 0.95, Money Flow Index : 74.48, ROC : 4.09, RSI : 60.11, STOCH (14,3) : 99.19, STOCH RSI : 1.00, UO : 53.39, Williams %R : -0.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edwards Lifesciences Corporation in the last 12-months were: Bernard J. Zovighian (Option Excercise at a value of $0), Bernard J. Zovighian (Sold 23 429 shares of value $2 287 543 ), Daveen Chopra (Option Excercise at a value of $1 649 657), Daveen Chopra (Sold 40 435 shares of value $3 231 206 ), Donald E. Bobo (Option Excercise at a value of $2 844 124), Donald E. Bobo (Sold 85 025 shares of value $7 719 874 ), Huimin Wang (Option Excercise at a value of $517 392), Huimin Wang (Sold 14 700 shares of value $1 496 203 ), Jean-Luc M. Lemercier (Option Excercise at a value of $990 519), Jean-Luc M. Lemercier (Sold 41 420 shares of value $4 220 033 ), Katie Szyman (Option Excercise at a value of $944 384), Katie Szyman (Sold 43 400 shares of value $4 894 641 ), Larry L. Wood (Option Excercise at a value of $2 395 071), Larry L. Wood (Sold 65 172 shares of value $6 045 882 ), Leslie Stone Heisz (Option Excercise at a value of $345 029), Leslie Stone Heisz (Sold 9 671 shares of value $742 942 ), Martha H. Marsh (Option Excercise at a value of $746 436), Martha H. Marsh (Sold 28 722 shares of value $3 104 563 ), Michael A. Mussallem (Option Excercise at a value of $10 285 415), Michael A. Mussallem (Sold 211 425 shares of value $18 186 294 ), Scott B. Ullem (Option Excercise at a value of $0)